Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.

[1]  V. Hasselblad,et al.  Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. , 2004, JAMA.

[2]  V. Hasselblad,et al.  Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. , 2004, JAMA.

[3]  Topol Ej,et al.  Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) Trial , 2004 .

[4]  E. Antman,et al.  Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. , 2003, American heart journal.

[5]  P. Armstrong,et al.  Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide , 2003 .

[6]  R. Califf,et al.  Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). , 2002, American heart journal.

[7]  J. Canto,et al.  Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors. , 2002, The American journal of cardiology.

[8]  R. Califf,et al.  Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. , 2002, European heart journal.

[9]  Deepak L. Bhatt,et al.  Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. , 2002, European heart journal.

[10]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[11]  R. Califf,et al.  The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.

[12]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[13]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[14]  L. Deckelbaum,et al.  Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. , 1999, International journal of cardiology.

[15]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[16]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .